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Alcohol-Associated Erythema
Pershing and co-workers investigated a potential 
genetic basis for alcohol-associated erythema 
as the function of polymorphisms in coding and 
non-coding regions of class IB alcohol dehydro-
genase (ADHIB). Following challenge with topi-
cal 5 M ethanol, isopropyl alcohol, propylene 
glycol, and butanol, they found that promoter 
polymorphisms form eight ADHIB haplotypes, 
with different frequencies in Caucasians vs. 
Asians, and exhibit variable gene expression and 
metabolic activity. They conclude that erythema 
following alcohol exposure is alcohol-type spe-
cific, has a pharmacogenetic basis related to ADHIB haplotype, and can be func-
tionally evaluated via Doppler velocimetry and reflectance colorimetry in vivo. 
See page 616
A New Disorder in UV-Induced Skin Cancer
Hashimoto et al. described a female 
Japanese patient who exhibited 
freckling and skin cancers in sun-
exposed areas but no photosen-
sitivity. UV sensitivity of primary 
fibroblasts (KPSX7 cells) from the 
subject approximated that of normal 
fibroblasts, and the patient had nei-
ther xeroderma pigmentosum nor 
Cockayne syndrome. KPSX7 cells’ 
host-cell reactivation (HCR) activity 
was reduced, and UV-damage endonuclease introduced into cells restored repair 
activity to almost normal levels. These results indicate that KPSX7 cells are defec-
tive for some types of repair activity in UV-damaged DNA. Future data collection 
in patients with defective HCR but normal function in other DNA-repair tests may 
establish a new pathologic model. See page 694
AFC Inhibits Mouse Skin Inflammation
Gordon et al. have shown that topical N-acetyl-S-
farnesyl-L-cysteine (AFC) inhibits edema and neu-
trophil infiltration in vivo in the mouse-ear acute 
inflammation model. AFC also inhibits inflam-
mation associated with allergic contact derma-
titis, demonstrating that it is effective against both 
innate and adaptive immune-based responses. 
AFC’s predicted mechanism of action differs from 
that of glucocorticoids and cyclooxygenase inhib-
itors; in contrast to these agents, AFC’s effects are 
limited to the application site . AFC—or other pre-
nylcysteine analogs retaining AFC’s unique prop-
erties—may be a novel anti-inflammatory therapeutic with fewer side effects than 
current agents. See page 643
CCR6 Directs T Cells 
to Skin
To assess the role of the 
chemokine receptor CCR6 in 
the development of contact 
hypersensitivity, Paradis et al. 
sensitized CCR6 knockout 
mice to the hapten oxazolone. 
After rechallenge, ear swelling 
was reduced 80% compared 
with wild-type controls. 
CCR6 was critical in directing 
immune-cell migration to the 
skin, but it did not impair T-
cell activation. These results 
suggest that CCR6 has an 
important role in the efferent 
arm of contact hypersensitivity 
and that CCR6 antagonists 
may be used to treat atopic 
dermatitis. See page 628 
Designer siRNAs
Hickerson et al. targeted 
the single-nucleotide 
keratin 6a (K6a) N171K 
mutation responsible for 
pachyonychia congenita (PC) 
and demonstrated that small 
interfering RNAs (siRNAs) can 
block expression of mutant 
K6a. Adding mutant-specific 
siRNAs to a dominant-negative 
PC-cell-culture model allowed 
normal filament formation, 
suggesting selective inhibition 
of mutant K6a. Co-delivering 
a firefly luciferase/mutant K6a 
bicistronic reporter construct 
and mutant-specific siRNAs 
to mouse footpads inhibited 
the fluorescent reporter. In 
addition, wild-type-specific 
siRNAs downregulated the 
expression of pre-existing 
endogenous K6a in human 
keratinocytes. These results 
suggest that delivering 
“designer siRNAs” may 
effectively treat numerous 
genetic disorders. See page 594 
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